Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

MdmX is a substrate for the deubiquitinating enzyme USP2a

Oncogene volume 29, pages 432–441 (2010)Cite this article

Abstract

It has previously been shown that ubiquitin-specific protease 2a (USP2a) is a regulator of the Mdm2/p53 pathway. USP2a binds to Mdm2 and can deubiquitinate Mdm2 without reversing Mdm2-mediated p53 ubiquitination. Overexpression of USP2a causes accumulation of Mdm2 and promotes p53 degradation. We now show that MdmX is also a substrate for USP2a. MdmX associates with USP2a independently of Mdm2. Ectopic expression of wild-type USP2a but not a catalytic mutant prevents Mdm2-mediated degradation of MdmX. This correlates with the ability of wild-type USP2a to deubiquitinate MdmX. siRNA-mediated knockdown of USP2a in NTERA-2 testicular embryonal carcinoma cells and MCF7 breast cancer cells causes destabilization of MdmX and results in a decrease in MdmX protein levels, showing that endogenous USP2a participates in the regulation of MdmX stability. The therapeutic drug, cisplatin decreases MdmX protein expression. USP2a mRNA and protein levels were also reduced after cisplatin exposure. The magnitude and time course of USP2a downregulation suggests that the reduction in USP2a levels could contribute to the decrease in MdmX expression following treatment with cisplatin. Knockdown of USP2a increases the sensitivity of NTERA-2 cells to cisplatin, raising the possibility that suppression of USP2a in combination with cisplatin may be an approach for cancer therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  • Barboza JA, Iwakuma T, Terzian T, El-Naggar AK, Lozano G . (2008). Mdm2 and Mdm4 loss regulates distinct p53 activities. Mol Cancer Res 6: 947–954.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bottger V, Bottger A, Garcia-Echeverria C, Ramos YF, van der Eb AJ, Jochemsen AG et al. (1999). Comparative study of the p53-mdm2 and p53-MDMX interfaces. Oncogene 18: 189–199.

    Article  CAS  PubMed  Google Scholar 

  • Campbell KJ, Witty JM, Rocha S, Perkins ND . (2006). Cisplatin mimics ARF tumor suppressor regulation of RelA (p65) nuclear factor-kappaB transactivation. Cancer Res 66: 929–935.

    Article  CAS  PubMed  Google Scholar 

  • Cullinane C, Mazur SJ, Essigmann JM, Phillips DR, Bohr VA . (1999). Inhibition of RNA polymerase II transcription in human cell extracts by cisplatin DNA damage. Biochemistry 38: 6204–6212.

    Article  CAS  PubMed  Google Scholar 

  • Cummins JM, Rago C, Kohli M, Kinzler KW, Lengauer C, Vogelstein B . (2004). Tumour suppression: disruption of HAUSP gene stabilizes p53. Nature 428: 1 p following 486.

    Article  PubMed  Google Scholar 

  • Danovi D, Meulmeester E, Pasini D, Migliorini D, Capra M, Frenk R et al. (2004). Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Mol Cell Biol 24: 5835–5843.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dayal S, Sparks A, Jacob J, Allende-Vega N, Lane DP, Saville MK . (2009). Suppression of the deubiquitinating enzyme USP5 causes the accumulation of unanchored polyubiquitin and the activation of p53. J Biol Chem 284: 5030–5041.

    Article  CAS  PubMed  Google Scholar 

  • Evans GL, Gralla JD . (1992). Cisplatin-induced imbalances in the pattern of chimeric marker gene expression in HeLa cells. Biochem Biophys Res Comm 184: 1.

    Article  CAS  PubMed  Google Scholar 

  • Fang S, Jensen JP, Ludwig RL, Vousden KH, Weissman AM . (2000). Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem 275: 8945–8951.

    Article  CAS  PubMed  Google Scholar 

  • Finch RA, Donoviel DB, Potter D, Shi M, Fan A, Freed DD et al. (2002). mdmx is a negative regulator of p53 activity in vivo. Cancer Res 62: 3221–3225.

    CAS  PubMed  Google Scholar 

  • Francoz S, Froment P, Bogaerts S, De Clercq S, Maetens M, Doumont G et al. (2006). Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc Natl Acad Sci USA 103: 3232–3237.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Giglio S, Mancini F, Gentiletti F, Sparaco G, Felicioni L, Barassi F et al. (2005). Identification of an aberrantly spliced form of HDMX in human tumors: a new mechanism for HDM2 stabilization. Cancer Res 65: 9687–9694.

    Article  CAS  PubMed  Google Scholar 

  • Gilkes DM, Chen L, Chen J . (2006). MDMX regulation of p53 response to ribosomal stress. EMBO J 25: 5614–5625.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gousseva N, Baker RT . (2003). Gene structure, alternate splicing, tissue distribution, cellular localization, and developmental expression pattern of mouse deubiquitinating enzyme isoforms Usp2-45 and Usp2-69. Gene Expr 11: 163–179.

    Article  CAS  PubMed  Google Scholar 

  • Graner E, Tang D, Rossi S, Baron A, Migita T, Weinstein LJ et al. (2004). The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. Cancer Cell 5: 253–261.

    Article  CAS  PubMed  Google Scholar 

  • Gu J, Kawai H, Nie L, Kitao H, Wiederschain D, Jochemsen AG et al. (2002). Mutual dependence of MDM2 and MDMX in their functional inactivation of p53. J Biol Chem 277: 19251–19254.

    Article  CAS  PubMed  Google Scholar 

  • Honda R, Yasuda H. . (2000). Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene 19: 1473–1476.

    Article  CAS  PubMed  Google Scholar 

  • Hu B, Gilkes DM, Farooqi B, Sebti SM, Chen J . (2006). MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. J Biol Chem 281: 33030–33035.

    Article  CAS  PubMed  Google Scholar 

  • Itahana K, Mao H, Jin A, Itahana Y, Clegg HV, Lindstrom MS et al. (2007). Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. Cancer Cell 12: 355–366.

    Article  CAS  PubMed  Google Scholar 

  • Kawai H, Wiederschain D, Kitao H, Stuart J, Tsai KK, Yuan ZM . (2003). DNA damage-induced MDMX degradation is mediated by MDM2. J Biol Chem 278: 45946–45953.

    Article  CAS  PubMed  Google Scholar 

  • Kruse JJ, Svensson JP, Huigsloot M, Giphart-Gassler M, Schoonen WG, Polman JE et al. (2007). A portrait of cisplatin-induced transcriptional changes in mouse embryonic stem cells reveals a dominant p53-like response. Mutat Res 617: 58–70.

    Article  CAS  PubMed  Google Scholar 

  • Lane DP, Benchimol S . (1990). p53: oncogene or anti-oncogene? Genes Dev 4: 1–8.

    Article  CAS  PubMed  Google Scholar 

  • Li M, Brooks CL, Kon N, Gu W . (2004). A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol Cell 13: 879–886.

    Article  CAS  PubMed  Google Scholar 

  • Li M, Chen D, Shiloh A, Luo J, Nikolaev AY, Qin J et al. (2002). Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 416: 648–653.

    Article  CAS  PubMed  Google Scholar 

  • Lin H, Yin L, Reid J, Wilkinson KD, Wing SS . (2001). Divergent N-terminal sequences of a deubiquitinating enzyme modulate substrate specificity. J Biol Chem 276: 20357–20363.

    Article  CAS  PubMed  Google Scholar 

  • Linke K, Mace PD, Smith CA, Vaux DL, Silke J, Day CL . (2008). Structure of the MDM2//MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans. Cell Death Differ 15: 841.

    Article  CAS  PubMed  Google Scholar 

  • Marine JC, Dyer MA, Jochemsen AG . (2007). MDMX: from bench to bedside. J Cell Sci 120: 371–378.

    Article  CAS  PubMed  Google Scholar 

  • Marine JC, Francoz S, Maetens M, Wahl G, Toledo F, Lozano G . (2006). Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ 13: 927–934.

    Article  CAS  PubMed  Google Scholar 

  • Meulmeester E, Maurice MM, Boutell C, Teunisse AF, Ovaa H, Abraham TE et al. (2005). Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2. Mol Cell 18: 565–576.

    Article  CAS  PubMed  Google Scholar 

  • Michael D, Oren M . (2003). The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol 13: 49–58.

    Article  CAS  PubMed  Google Scholar 

  • Migliorini D, Lazzerini Denchi E, Danovi D, Jochemsen A, Capillo M, Gobbi A et al. (2002). Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development. Mol Cell Biol 22: 5527–5538.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Montes de Oca Luna R, Wagner DS, Lozano G . (1995). Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378: 203–206.

    Article  CAS  PubMed  Google Scholar 

  • Parant J, Chavez-Reyes A, Little NA, Yan W, Reinke V, Jochemsen AG et al. (2001). Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat Genet 29: 92–95.

    Article  CAS  PubMed  Google Scholar 

  • Park KC, Kim JH, Choi EJ, Min SW, Rhee S, Baek SH et al. (2002). Antagonistic regulation of myogenesis by two deubiquitinating enzymes, UBP45 and UBP69. Proc Natl Acad Sci USA 99: 9733–9738.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Patton JT, Mayo LD, Singhi AD, Gudkov AV, Stark GR, Jackson MW . (2006). Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res 66: 3169–3176.

    Article  CAS  PubMed  Google Scholar 

  • Previati M, Lanzoni I, Corbacella E, Magosso S, Giuffre S, Francioso F et al. (2004). RNA expression induced by cisplatin in an organ of Corti-derived immortalized cell line. Hear Res 196: 8–18.

    Article  CAS  PubMed  Google Scholar 

  • Priolo C, Tang D, Brahamandan M, Benassi B, Sicinska E, Ogino S et al. (2006). The isopeptidase USP2a protects human prostate cancer from apoptosis. Cancer Res 66: 8625–8632.

    Article  CAS  PubMed  Google Scholar 

  • Renatus M, Parrado SG, D'Arcy A, Eidhoff U, Gerhartz B, Hassiepen U et al. (2006). Structural basis of ubiquitin recognition by the deubiquitinating protease USP2. Structure 14: 1293–1302.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Shvarts A, Steegenga WT, Riteco N, van Laar T, Dekker P, Bazuine M et al. (1996). MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J 15: 5349–5357.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Siddik ZH . (2003). Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265–7279.

    Article  CAS  PubMed  Google Scholar 

  • Singh RK, Iyappan S, Scheffner M . (2007). Hetero-oligomerization with MdmX rescues the ubiquitin/Nedd8 ligase activity of RING finger mutants of Mdm2. J Biol Chem 282: 10901–10907.

    Article  CAS  PubMed  Google Scholar 

  • Stevenson LF, Sparks A, Allende-Vega N, Xirodimas DP, Lane DP, Saville MK . (2007). The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2. EMBO J 26: 976–986.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Stommel JM, Wahl GM . (2004). Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation. EMBO J 23: 1547–1556.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tanimura S, Ohtsuka S, Mitsui K, Shirouzu K, Yoshimura A, Ohtsubo M . (1999). MDM2 interacts with MDMX through their RING finger domains. FEBS Lett 447: 5–9.

    Article  CAS  PubMed  Google Scholar 

  • Toledo F, Krummel KA, Lee CJ, Liu CW, Rodewald LW, Tang M et al. (2006). A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network. Cancer Cell 9: 273–285.

    Article  CAS  PubMed  Google Scholar 

  • Toledo F, Wahl GM . (2007). MDM2 and MDM4: p53 regulators as targets in anticancer therapy. Int J Biochem Cell Biol 39: 1476–1482.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Uldrijan S, Pannekoek WJ, Vousden KH . (2007). An essential function of the extreme C terminus of MDM2 can be provided by MDMX. EMBO J 26: 102–112.

    Article  CAS  PubMed  Google Scholar 

  • Vassilev LT . (2007). MDM2 inhibitors for cancer therapy. Trends Mol Med 13: 23–31.

    Article  CAS  PubMed  Google Scholar 

  • Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al. (2004). in vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303: 844–848.

    Article  CAS  PubMed  Google Scholar 

  • Vichi P, Coin F, Renaud JP, Vermeulen W, Hoeijmakers JH, Moras D, Egly JM . (1997). Cisplatin- and UV-damaged DNA lure the basal transcription factor TFIID/TBP. EMBO J 16: 7444–7456.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Vousden KH, Lu X . (2002). Live or let die: the cell's response to p53. Nat Rev Cancer 2: 594–604.

    Article  CAS  PubMed  Google Scholar 

  • Wade M, Wahl GM . (2009). Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry? Mol Cancer Res 7: 1–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wade M, Wong ET, Tang M, Stommel JM, Wahl GM . (2006). Hdmx modulates the outcome of p53 activation in human tumor cells. J Biol Chem 281: 33036–33044.

    Article  CAS  PubMed  Google Scholar 

  • Wang YV, Wade M, Wong E, Li Y-C, Rodewald LW, Wahl GM . (2007). Quantitative analyses reveal the importance of regulated Hdmx degradation for P53 activation. Proc Natl Acad Sci 104: 12365–12370.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Xia M, Knezevic D, Tovar C, Huang B, Heimbrook DC, Vassilev LT . (2008). Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation. Cell Cycle 7: 1604–1612.

    Article  CAS  PubMed  Google Scholar 

  • Xirodimas D, Saville MK, Edling C, Lane DP, Lain S . (2001). Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo. Oncogene 20: 4972–4983.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was funded by Cancer Research UK. Professor David P Lane is a Gibb fellow of Cancer Research UK.

Author information

Authors and Affiliations

  1. Division of Molecular Medicine, Department of Surgery and Molecular Oncology, CR-UK Cell Transformation Research Group, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK

    N Allende-Vega, A Sparks, D P Lane & M K Saville

Authors
  1. N Allende-Vega
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Sparks
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D P Lane
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M K Saville
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M K Saville.

Additional information

Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc)

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Allende-Vega, N., Sparks, A., Lane, D. et al. MdmX is a substrate for the deubiquitinating enzyme USP2a. Oncogene 29, 432–441 (2010). https://doi.org/10.1038/onc.2009.330

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2009.330

Keywords

This article is cited by

Search

Advanced search

Quick links